ã·ã³ã¬ãã¼ã«ããæ°åã³ããã¦ã£ã«ã¹ (COVID-19) ã®å½±é¿ãåãã¦ãã¾ãã
ããã«è² ããªãããã«ã¯ãä¿¡é ¼ã§ããã½ã¼ã¹ããã®ãã®ãæ²è¼ãã¦ãã¾ããã·ã³ã¬ãã¼ã«æ¿åºã»WHOãªã©å½é£æ©é¢ãå°å
大æã¡ãã£ã¢(ã¹ãã¬ã¼ãã¿ã¤ã ãºç´ãCNA)ãªã©ã§ããå¯è½ãªéããç§ã®ããã°ã§ã¯ãªããåæã«ããã£ã¦ãã ããã
æ´æ°æ å ±ã®ãµããªã¼
- 18ï½49æ³ã«2度ç®ã®ãã¼ã¹ã¿ã¼æ¥ç¨®ã対象ã«ã11æ7æ¥ä»¥éã2価ã¯ã¯ãã³ã«ãªããSMSããã®äºç´ãå¿ è¦ã
ã¾ãã¯40ï½49æ³ã対象ã
- 12åã®ARTããããåä¸å¸¯ã«é å¸ãããã11æ21æ¥ãã
- BQ.1ã¨BQ.1.1ãã·ã³ã¬ãã¼ã«ã«ä¸é¸ã
- å»çå¾äºè ã2価ã¯ã¯ãã³æ¥ç¨®å¯¾è±¡ã«è¿½å ãããã
- ææ¥å¤æ¥ããç æ£ã«å ¥é¢ããã¾ã§2æ¥ä»¥ä¸ãããæ£è ãåºã¦ããã
- 3,128äººãæ°è¦ææãå 訳ã¯ãè¼¸å ¥ã187人ãå¸ä¸ææã2,941人ãé±ã®ææè å¢å çã¯0.69ãå ¥é¢ã444人ãICUã«16äººãæ°è¦ã®æ»è 2äººãæ»è åè¨ã1,685人ã
Rã1ãåã£ã¦15æ¥ç®ã
ã·ã³ã¬ãã¼ã«ã§ã®ææ°ç¶æ³
æ´æ°æ å ±
æ¥æ | çºä¿¡è (ã½ã¼ã¹ã¨ãªããªã³ã¯) | å 容 |
---|---|---|
2022å¹´11æ4æ¥ | 保健省 | 3,128äººã®æ°è¦ææè
ãè¦ã¤ãããéç®ã§2,118,749人ã«ãªã£ããæ°è¦ã®ãã¡ãPCR輸å
¥ã12人ãART輸å
¥ã175人ãPCRå¸ä¸ææã306人ãARTå¸ä¸ææã2,635人ãé±ã®ææè
å¢å çã¯0.69ãç¾å¨ã444人ãå
¥é¢ä¸(ãã¡éçã®ICUã16人)ã2人ã亡ããªã£ããããã¾ã§ã«1,685人ã亡ããªã£ã¦ããã ã¯ã¯ãã³å®å ¨æ¥ç¨®ã¯92%ã1åæ¥ç¨®ã¯93%ããã¼ã¹ã¿ã¼æ¥ç¨®ã¯80%ã |
2022å¹´11æ4æ¥ | 保健省 | å¤çåºã¿ã¹ã¯ãã©ã¼ã¹ã¯XBBå¤ç°ç¨®ã«ããææè
æ°å¢å ãæ³¨è¦ãã¦ãããXBBæææ³¢ã¯è½ã¡çããã¨ææãããè¤æ°ã®å¤ç°ç¨®ãä¸çä¸ã«ãããç¶æ³ã«çãã訳ã«ã¯ãããªãã 3ã¤ã®é²å¾¡ã©ã¤ã³ãããã1ã¤ç®ã¯ã¯ã¯ãã³ãææ°ã«ä¿ã¤ãã¨ãã·ã³ã¬ãã¼ã«ã®é«ãæ¥ç¨®çã«ãã£ã¦ãéçã¨æ»äº¡æ°ãä»å½ããæãããã¦ããã11æ2æ¥æç¹ã§ã6ä¸5å人ã2価ã¯ã¯ãã³ãæ¥ç¨®æ¸ã¿ãäºç´æ¸ã¿ã ã 11æ7æ¥ä»¥éã18ï½49æ³ãå¾ã ã«2価ã¯ã¯ãã³æ¥ç¨®ã«æãã対象è ã¯ãçµ±åæ¤æ»ã¯ã¯ãã³ã»ã³ã¿ã¼JTVCã§ã®åå¥ã®äºç´ãªã³ã¯ãSMSã§åãåããã¾ãã¯ã40ï½49æ³ã®å人ã対象ã ããã®å¾å¾ã ã«ãè¥ã年齢層ã«ç§»ã£ã¦ãããå ¨å¡ã«SMSãæ¸¡ãã«ã¯æ°é±éããããJTVCã§ã®äºç´ç¡ãæ¥ç¨®ã¯ã50æ³ä»¥ä¸ã¨å»çå¾äºè ã®ã¿ã¨ãªããJTVCã®éå¶æéã¯ããã¡ããåç §ã®ãã¨ã https://www.gowhere.gov.sg/vaccine 12æ³ä»¥ä¸ã«ããã¡ã¤ã¶ã¼2価ã¯ã¯ãã³ãæ¿èªããããã¯ã¯ãã³å°çã¯å¹´æ«ãäºå®ãã¦ããã 18æ³ä»¥ä¸ã¯ãã¯ã¯ãã³ãææ°ã«ãã¦ãããã¨ãæå¾ã®åºæ¬æ¥ç¨®ããã5ã¶æï½1年以å ã«è¿½å ã®ãã¼ã¹ã¿ã¼æ¥ç¨®ãåãããã¨ã2価ã¯ã¯ãã³ãæ¨å¥¨ãããã 2ã¤ç®ã®é²è¡ã©ã¤ã³ã¯å®æçãªèªå·±æ¤æ»ã ãå¤çåºã¿ã¹ã¯ãã©ã¼ã¹ã¯4度ç®ã®ARTããããé å¸ãããåä¸å¸¯ã¯12ARTããããåãåããé å¸ã¯11æ21æ¥ããã 使å¾ä¸å¸¯ã¯è¿½å ã§ARTããããè¦æã§ããã 3ã¤ç®ã®é²è¡ã©ã¤ã³ã¯ãå人ã¨ç¤¾ä¼è²¬ä»»ã ã |
2021å¹´10æ26æ¥ | ストレートタイムズ紙 | 10æ23æ¥ã«ãBQ.1ã¨BQ.1.1å¤ç°ç¨®ã«ææãã4人ãã·ã³ã¬ãã¼ã«ã§è¦ã¤ãã£ããå ¨å¡ãè¼¸å ¥ã§ã誰ãå ¥é¢ãã¦ããªããä¿å¥çMOHãè¿°ã¹ããBQ.1ã¨BQ.1.1ã¯BA.5ããææãæãå¯è½æ§ãããããããéçåããã証æ ã¯ç¾å¨ãªããBA.5ã®ç³»çµ±ã ãä¸ççãªå²åã¯å°ãªãããæ¬§å·ã¨åç±³ã§å¢å ãã¦ãããç±³å½CDCã¯ãç±³å½å ã§16.6%ã«ãªãã¨æ¨å®ãã¦ããã |
2022å¹´10æ25æ¥ | 健康科学局 (HSA) | HSAã¯ãã¡ã¤ã¶ã¼ç¤¾ã®Cominarty Covid-19 2価(ãªãªã¸ãã«ã¨ãªãã¯ãã³BA.4/5)ã¯ã¯ãã³ããã³ãããã¯ã¹ãã·ã£ã«ã¢ã¯ã»ã¹ã«ã¼ãPSARã§æ«å®æ¿èªãããããã¯å ã®Cominartyã¯ã¯ãã³ããã®ã¢ãããã¼ãã§ããªãªã¸ãã«ã®SARS-CoV-2ãæ¨çã«ãã15ããªã°ã©ã ã¨ããªãã¯ãã³BA.4ã¨BA.5å¤ç°ç¨®ãæ¨çã«ãã15ããªã°ã©ã ã®2ã¤ããæ§æããã¦ãããæ¿èªå¯¾è±¡ã¯ã12æ³ä»¥ä¸ã¸ã®ãã¼ã¹ã¿ã¼ã¯ã¯ãã³ã§ã®å©ç¨ã ã |
2022å¹´10æ21æ¥ | 保険省 | å»çå¾äºè ã«ã¢ãã«ã社ã¹ãã¤ã¯ããã¯ã¹ã®Covid-19 2価ã¯ã¯ãã³ã対象æ¡å¤§ãããå ¬å¶æ½è¨ã»ç§å¶æ½è¨ãå«ãã対象ã®å»çå¾äºè ã¯ã18æ³ä»¥ä¸ã§ãæä½3åã®mRNAã¯ã¯ãã³ãNuvaxovidã4åã®ã·ãããã¯ãæ¥ç¨®ãã¦æä½éã®ä¿è·ãéæãã¦ãããæå¾ã®æ¥ç¨®ãã5ã¶æä»¥ä¸çµã£ã¦ãããã¨ã9ã¤ããå忤æ»ã¯ã¯ãã³ã»ã³ã¿ã¼JTVCã§æ¥ç¨®ã§ããã¹ã¿ããè¨¼ææ¸ãæç¤ºãããã¨ãå¤åå ããã®ã¡ã¢ã§ãããã |
2022å¹´10æ20æ¥ | ストレートタイムズ紙 | å
¬å¶ç
é¢ã®ãããä¸è¶³ãæ·±å»ã«ãªããææ¥å¤æ¥EDããæº¢ãåºãã¦ãããå
¥é¢ã§ããªããææ¥è»ã§æ¬éããã¦ããæ£è
ãç½®ãå ´æããªããæ
æ¶ã«ç½®ããªãã診æãããæ¥ãããã¨ææ¥å¤æ¥å»å¸«ã¯è¨ããéçæ£è
ã¯å³åº§ã«è¨ºå¯ãåãã¦ãããããã§ãªããã°ãç§»éããææ¥è»ãé¢ããã¾ã§ã«ãå ´æã®ç¢ºä¿ã«15ï½30åå¾
ã£ã¦ãããæ¬¡ã®éçæ£è
ãå¿
è¦ãªææ¥è»ãæãã¦ãããã¨ã«ãªãã 2022å¹´ã®ä¸åæã§ãæ¨å¹´æ¯33%ã®ææ¥é»è©±ã®å¢å ãããããã¡93%ã¯å®éã«ææ¥ã ã£ããç æ£ã«ããããå¢ãããææ¥å¤æ¥ã«å¾ åå ´æãå¢ãããã¨ãã¦ããã¨ä¿å¥çMOHã¯è¨ãã ããæ°å¹´æ ¢æ§çã ããCovid-19ææè ã®å¢å ã§ä»å¹´ã«å ¥ã£ã¦æªåãã¦ããã¨ãææ¥å¤æ¥ã®å»å¸«ã¨çè·ã¯è¨ãããEDã«æ°æ¥ãã£ã¦ãæ£è ãæ®ã£ã¦ããæããããããç·æ§æ£è 91æ³ã¯ã2æ¥3æéãã£ã¦ãææ¥å¤æ¥ã«ããã æ£è å¢å ã«å ãã¦ãå ¬å¶ç é¢ã¯å¤ãã®ã¸ã¥ãã¢å»å¸«ãé¢è·ããããã³ãããã¯é¢ä¿ã®æ°ã¶æã®ä»äºã§ãç é¢ã§ã®1年以ä¸ã®ç¨¼ããå¾ãããããã ãæ¸¡èªå¶éãè§£ãããå¤å½äººçè·å¸«ãæ¯å½ã«å¸°ã£ã¦ãã£ããã伿©ãã¨ããªãããã¤ã¬ã«ãè¡ããªããæ¬¡ã®ã·ããã®äººãããããæ®æ¥ãå¿ è¦ã«ãªããã¨çè·å¸«ã¯è¨ãã |
ããã¾ã§ã®æ°åã³ããã¦ã¤ã«ã¹è¨äº
ããã¾ã§ã®æ´æ°æ
å ±ã®ç·éç·¨ã¯ããã¡ããåç
§ãã ããã
uniunichan.hatenablog.com
ãå¥åº·ãªäººã«ã¯ãã¹ã¯ã¯å¹æããªãããã·ã³ã¬ãã¼ã«æ¿åºã®ç«å ´ã§ããããçºçåã«ææããã人ã確èªãããåå©ç¨å¯è½ãã¹ã¯ãé
å¸ãç¾å¨ã¯ãå¤åºæã®ãã¹ã¯çç¨ãå¿
é ã«ã
uniunichan.hatenablog.com